HKMPF - Hikma Pharmaceuticals GAAP EPS of $76.20 revenue of $1.21B misses by $10M
- Hikma Pharmaceuticals press release ( OTCPK:HKMPF ): 1H GAAP EPS of $76.20.
- Revenue of $1.21B (flat Y/Y) misses by $10M .
- Outlook for full year 2022:
- Injectables – we continue to expect revenue growth to be in the mid to high-single digits and core operating margin to be between 36% to 37%
- Branded – we now expect revenue to grow in the low-single digits on a reported basis. On a constant currency basis, we expect Branded revenue to grow in the mid-single digits. We expect core operating profit to be more evenly split across the year
- Generics – we now expect revenue to be in the range of $650 million to $675 million and core operating margin to be between 15% to 16%
For further details see:
Hikma Pharmaceuticals GAAP EPS of $76.20, revenue of $1.21B misses by $10M